Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 10/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | SELL | P14151 | 1/20 | 0.35 |
| ▸ | SELP | P16109 | 1/20 | 0.35 |
| ▸ | SELE | P16581 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31633777 | 1.00 | RAPGEF4 (0.43) | RAPGEF4HDAC1HDAC6ACHESELL | |
| SCHEMBL30668 | 0.84 | HDAC1 (0.48) | RAPGEF4HDAC1HDAC6ACHESELL | |
| SCHEMBL18541877 | 0.79 | RAPGEF4 (0.42) | RAPGEF4HDAC1HDAC6CA1CA2 | |
| Nitrogen SCHEMBL10699058 | 0.79 | HDAC1 (0.44) | RAPGEF4HDAC1HDAC6ACHESELL | |
| SCHEMBL28951 | 0.77 | RAPGEF4 (0.59) | RAPGEF4ACHECA1CA2MMP1 | |
| SCHEMBL1551822 | 0.77 | RAPGEF4 (0.59) | RAPGEF4ACHECA1CA2MMP1 | |
| SCHEMBL30867014 | 0.77 | RAPGEF4 (0.43) | RAPGEF4HDAC1HDAC6ACHECA1 | |
| SCHEMBL8268053 | 0.77 | RAPGEF4 (0.52) | RAPGEF4ACHESELLSELPSELE | |
| SCHEMBL8446400 | 0.77 | RAPGEF4 (0.43) | RAPGEF4HDAC1HDAC6ACHECA1 | |
| SCHEMBL13087003 | 0.74 | RAPGEF4 (0.38) | RAPGEF4HDAC1HDAC6ACHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023198671-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2023-10-19 | — | — | WO | disclosed |
| US-20230313043-A1 | OPTICAL COMPONENT | MERCK PATENT GMBH (DE) | 2023-10-05 | — | — | US | disclosed |
| US-20230303495-A9 | PYRIDINE OXYNITRIDE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEYOU PHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| WO-2023174896-A1 | ELECTRONIC SWITCHING DEVICE | MERCK PATENT GMBH (DE) | 2023-09-21 | — | — | WO | disclosed |
| US-20230301173-A1 | ELECTRONIC SWITCHING DEVICE | MERCK PATENT GMBH (DE) | 2023-09-21 | — | — | US | disclosed |
| EP-4247138-A1 | ELECTRONIC SWITCHING DEVICE | Merck Patent GmbH (DE) | 2023-09-20 | — | — | EP | disclosed |
| EP-3877484-B1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | MERCK PATENT GMBH (DE) | 2023-09-13 | — | — | EP | disclosed |
| EP-3739020-B1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2023-08-23 | — | — | EP | disclosed |
| US-11634445-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-04-25 | — | — | US | disclosed |
| WO-2022266162-A1 | AZETIDINYL COMPOUNDS COMPRISING A CARBOXYLIC ACID GROUP FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2022-12-22 | — | — | WO | disclosed |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| WO-2008092491-A1 | CHROMAN COMPOUNDS FOR USE AS COMPONENTS IN LIQUID-CRYSTALLINE MEDIA, FOR EXAMPLE IN ELECTROOPTICAL DISPLAY ELEMENTS | MERCK PATENT GMBH (DE) | 2008-08-07 | — | — | WO | disclosed |
| EP-1911828-A1 | Liquid crystal display | Merck Patent GmbH (DE) | 2008-04-16 | — | — | EP | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070176144-A1 | Liquid crystal composition for bistable liquid crystal devices | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2007-08-02 | — | — | US | disclosed |
| US-7247355-B2 | Liquid crystal compound having chroman ring, liquid crystal composition comprising the compound and liquid crystal display device comprising the composition | CHISSO CORPORATION (JP) | 2007-07-24 | — | — | US | disclosed |
| US-7247355-B2 | Liquid crystal compound having chroman ring, liquid crystal composition comprising the compound and liquid crystal display device comprising the composition | CHISSO CORPORATION (JP) | 2007-07-24 | — | — | US | disclosed |
| WO-2007071585-A1 | PESTCIDAL COMPOSITIONS | BASF SE (DE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PIGS, GP6, ASGR1 | RAPGEF4 2022/4885HDAC1 2831/4885HDAC6 1406/4885 |
| US-20230301173-A1 | ELECTRONIC SWITCHING DEVICE | OR10J3, L1CAM, GRM6 | RAPGEF4 1405/4885HDAC1 4844/4885HDAC6 4879/4885 |
| US-20230303495-A9 | PYRIDINE OXYNITRIDE, PREPARATION METHOD THEREFOR AND USE THEREOF | SCN11A, HCN4, CACNA1F | RAPGEF4 758/4885HDAC1 2195/4885HDAC6 3029/4885 |
| US-11634445-B2 | Organic electroluminescent materials and devices | L1CAM, EPCAM, SOD1 | RAPGEF4 1256/4885HDAC1 3297/4885HDAC6 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.